Active material: Vinpocetine
When ATH: N06BX18
CCF: Preparation, improves blood circulation and metabolism of the brain
When CSF: 02.15
Manufacturer: Chemical-Pharmaceutical Plant JSC QUINACRINE (Russia)
Pills white or white with a yellowish tint, Valium, chamfered, allowed marbling.
| 1 tab. | |
| Vinpocetine | 5 mg |
Excipients: lactose, colloidal silicon dioxide (aэrosyl), potato starch, magnesium stearate.
10 PC. – упаковки ячейковые контурные (5) – пачки.
50 PC. – упаковки ячейковые контурные (1) – пачки.
Means, improve cerebral blood flow and cerebral metabolism. It inhibits the activity of phosphodiesterase, which contributes to the accumulation of cAMP in the tissues. Preferably has a vasodilating effect on brain vessels, due to a direct antispasmodic effect miotropnym. Systemic blood pressure decreased slightly. It improves blood circulation and microcirculation in the brain tissue, reduces platelet aggregation, It helps to normalize blood rheology. Improves tolerance of hypoxia brain cells, promoting oxygen transport to the tissues due to reduced affinity thereto erythrocytes, enhancing uptake and glucose metabolism. Increases the content of catecholamines in the brain tissue.
If ingestion is rapidly absorbed from the digestive tract. Cmax in plasma is approximately 1 no. In parenteral administration, Vd is 5.3 l / kg. T1/2 is about 5 no.
Acute and chronic cerebral circulatory insufficiency. Encephalopathy, accompanied by memory disorders, dizziness, headache. traumatic encephalopathy. Vascular diseases of the retina and choroid. Hearing impairment of vascular or toxic origin, Meniere's disease, dizziness labyrinth origin. Vascular dystonia with climacteric syndrome.
Для приема внутрь – по 5-10 mg 3 times / day.
The injection (mostly in acute conditions) single dose of 20 mg, with good endurance increase the dose over a 3-4 days before 1 mg / kg; length of treatment 10-14 days.
Cardio-vascular system: Transient hypertension, tachycardia; редко – экстрасистолия, ventricular enlargement excitation time.
Pregnancy, hypersensitivity to vinpocetine.
For parenteral administration: severe coronary artery disease, severe arrhythmia.
Contraindicated during pregnancy.
safety data, use during lactation are absent.
To use caution inside with arrhythmia, angina, unstable when reduced blood pressure and vascular tone. Parenteral, usually, is used in severe cases, to improve the clinical picture, then move on ingestion. In chronic diseases vinpocetine are inside. In hemorrhagic cerebral stroke parenteral administration of vinpocetine is allowed only after the reduction of acute effects (usually 5-7 days).
In an application with warfarin reported a slight decrease in the anticoagulant action of warfarin.
With simultaneous parenteral administration of vinpocetine and heparin may increase the risk of bleeding.
This site uses cookies and services to collect technical data from visitors to ensure performance and improve the quality of service.. By continuing to use our site, you automatically agree to the use of these technologies.
Read More